勃林格殷格翰首次启动人用药本地化生产，确保降糖药在华稳定供应

Core Insights - The localization production initiative by Boehringer Ingelheim marks a significant step in the company's strategic expansion in China, transitioning from commercial operations to deeper involvement in the industrial chain [1] - The launch of the local production plan for the diabetes drug Onglyza (linagliptin) is aimed at enhancing supply stability in the Chinese market and optimizing production capabilities at the Shanghai facility [1][3] - Boehringer Ingelheim plans to invest over 5 billion RMB in R&D in China over the next five years, focusing on metabolic diseases, inflammation, eye health, and oncology [3] Company Developments - Onglyza, a previously top-selling diabetes medication in China, was approved in 2013 and has seen significant sales, exceeding 1.3 billion RMB in 2023 [3] - The Shanghai biopharmaceutical base of Boehringer Ingelheim has received certifications from major global drug regulatory agencies, positioning it as a key player in the domestic biopharmaceutical contract manufacturing sector [4] - The company is part of a broader trend where multinational pharmaceutical firms are increasing investments in China's biopharmaceutical sector, driven by rising demand for innovative drugs [4] Industry Context - The 37th Shanghai International Business Leaders Advisory Council (IBLAC) highlighted the importance of innovation in Shanghai's strategic development, with calls for a supportive market environment to foster innovation [4] - The upcoming 2025 Shanghai International Biopharmaceutical Industry Week aims to gather experts and industry representatives to discuss overcoming barriers and enhancing collaboration in the biopharmaceutical field [5]